Image Analysis Group (IAG), a leader in clinical trial imaging and AI-enhanced biomarkers, has bolstered its U.S. operations by establishing a new office in Cambridge, Massachusetts. This strategic expansion positions IAG closer to key biotechnology and pharmaceutical companies in the Boston area, facilitating stronger partnerships and offering direct support for clinical trials within the region. The Cambridge office will enhance IAG’s capacity to collaborate with sponsors and contract research organizations that are engaged in Phase I-III clinical trials and imaging-centric development programs.
The new location will serve as a hub for IAG’s work across diverse therapeutic areas such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. With this expansion, IAG plans to generate local job opportunities, aiming to hire across various functions including clinical imaging operations, data science, regulatory support, and business development over the next 12 to 24 months. This move is set to bolster the company’s end-to-end imaging services, which encompass clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery.
By embedding itself within the thriving Boston life-sciences ecosystem, IAG anticipates improved collaboration with biotechnology firms, pharmaceutical entities, academic institutions, and clinical research centers. The firm supports clinical trials not only in North America but also across Europe and the Asia-Pacific region, working with a range of pharmaceutical, biotechnology, and medical technology companies, as well as contract research organizations (CROs) on multi-center studies. Its international presence ensures standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for global trials.
Founded in 2007 and headquartered in London, IAG functions as an imaging Clinical Research Organization (iCRO). The company lends its expertise to pharmaceutical, biotechnology, and medical technology companies through imaging-based clinical trial endpoints. IAG’s innovative DYNAMIKA™ platform is a cornerstone of its offerings, featuring AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight. By expanding its footprint in the U.S., IAG aims to further its mission of advancing clinical trial imaging and biomarker development.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.